Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 5/20 | 0.34 |
| ▸ | IDH1 | O75874 | 3/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.34 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | JAK2 | O60674 | 3/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1296417 | 1.00 | ACACB (0.35) | ACACBMAPTPOLBGPR119KCNH2 | |
| SCHEMBL1296354 | 0.88 | ACACB (0.38) | ACACBMAPTPOLBGPR119KCNH2 | |
| SCHEMBL1296353 | 0.88 | ACACB (0.38) | ACACBMAPTPOLBGPR119KCNH2 | |
| SCHEMBL1294960 | 0.85 | GPR119 (0.39) | ACACBMAPTPOLBGPR119KCNH2 | |
| SCHEMBL1294970 | 0.85 | GPR119 (0.39) | ACACBMAPTPOLBGPR119KCNH2 | |
| SCHEMBL1295740 | 0.82 | GPR119 (0.36) | ACACBGPR119KCNH2 | |
| SCHEMBL1296499 | 0.82 | GPR119 (0.36) | ACACBGPR119KCNH2 | |
| SCHEMBL1295735 | 0.82 | GPR119 (0.36) | ACACBGPR119KCNH2 | |
| SCHEMBL1295695 | 0.80 | GPR119 (0.39) | MAPTPOLBGPR119JAK2NTRK1 | |
| SCHEMBL1295698 | 0.80 | GPR119 (0.39) | MAPTPOLBGPR119JAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2011-11-03 | — | — | US | disclosed |
| EP-2321297-A1 | PIPERIDINYL GPCR AGONISTS | Prosidion Limited (GB) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010004343-A1 | PIPERIDINYL GPCR AGONISTS | PROSIDION LIMITED (GB) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269734-A1 | PIPERIDINYL GPCR AGONISTS | GPR119, GPR27, GLP1R | ACACB 3305/4885MAPT 4100/4885POLB 4252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.